Valeo Financial Advisors LLC boosted its position in shares of UnitedHealth Group Inc (NYSE:UNH) by 35.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,198 shares of the healthcare conglomerate’s stock after purchasing an additional 1,866 shares during the quarter. Valeo Financial Advisors LLC’s holdings in UnitedHealth Group were worth $2,116,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. Bamco Inc. NY raised its stake in UnitedHealth Group by 31.1% in the 2nd quarter. Bamco Inc. NY now owns 4,179 shares of the healthcare conglomerate’s stock valued at $1,020,000 after acquiring an additional 992 shares during the period. Cambridge Investment Research Advisors Inc. increased its holdings in shares of UnitedHealth Group by 12.4% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 110,266 shares of the healthcare conglomerate’s stock worth $26,906,000 after purchasing an additional 12,133 shares during the period. Smith Moore & CO. raised its position in shares of UnitedHealth Group by 1.3% in the second quarter. Smith Moore & CO. now owns 3,156 shares of the healthcare conglomerate’s stock valued at $770,000 after buying an additional 41 shares in the last quarter. Mutual Advisors LLC raised its position in shares of UnitedHealth Group by 3.1% in the second quarter. Mutual Advisors LLC now owns 7,264 shares of the healthcare conglomerate’s stock valued at $1,773,000 after buying an additional 217 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. raised its position in shares of UnitedHealth Group by 24.1% in the second quarter. Amundi Pioneer Asset Management Inc. now owns 1,464,736 shares of the healthcare conglomerate’s stock valued at $912,447,000 after buying an additional 284,094 shares in the last quarter. Institutional investors own 85.79% of the company’s stock.
In other news, CAO Thomas E. Roos sold 1,177 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $255.04, for a total value of $300,182.08. Following the completion of the transaction, the chief accounting officer now directly owns 21,687 shares in the company, valued at approximately $5,531,052.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP D Ellen Wilson sold 7,400 shares of the stock in a transaction on Monday, November 18th. The shares were sold at an average price of $272.77, for a total value of $2,018,498.00. In the last three months, insiders have sold 23,577 shares of company stock valued at $6,810,430. Insiders own 0.87% of the company’s stock.
UnitedHealth Group (NYSE:UNH) last released its quarterly earnings data on Wednesday, January 15th. The healthcare conglomerate reported $3.90 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.13. The business had revenue of $60.90 billion for the quarter, compared to analyst estimates of $61.17 billion. UnitedHealth Group had a return on equity of 25.55% and a net margin of 5.71%. UnitedHealth Group’s revenue was up 4.3% compared to the same quarter last year. During the same period last year, the firm posted $3.28 earnings per share. As a group, equities research analysts predict that UnitedHealth Group Inc will post 16.47 EPS for the current year.
UNH has been the topic of a number of analyst reports. Oppenheimer increased their price target on UnitedHealth Group from $312.00 to $343.00 and gave the stock an “outperform” rating in a research report on Thursday, January 16th. UBS Group lifted their price objective on UnitedHealth Group from $279.00 to $304.00 and gave the company a “neutral” rating in a report on Thursday, January 16th. Argus reiterated a “buy” rating and set a $340.00 target price on shares of UnitedHealth Group in a research report on Thursday, December 19th. Wells Fargo & Co reissued an “overweight” rating and set a $335.00 target price (up from $318.00) on shares of UnitedHealth Group in a report on Wednesday, December 11th. Finally, Credit Suisse Group increased their target price on UnitedHealth Group from $320.00 to $330.00 and gave the stock an “outperform” rating in a report on Wednesday, January 8th. Five investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. UnitedHealth Group currently has a consensus rating of “Buy” and an average target price of $313.50.
About UnitedHealth Group
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Inc (NYSE:UNH).
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.